Recently, Guangdong Provincial Department of science and technology and Guangdong Provincial Department of Taxation jointly issued the certificate of biotechnology.
Guangzhou Boji biomedical science and Technology Park Co., Ltd., a holding subsidiary of Boji Medical Technology Co.Ltd(300404) was established in July 2014 with a registered capital of 176 million yuan and officially put into operation in early 2019. Located at No. 3, Chuangye Road, Zengcheng economic and Technological Development Zone, Guangzhou, covering an area of 33000 m2 and a total planned construction area of 100000 m2, the park is a platform integrating cdmo R & D, pilot production and biomedical professional incubator. The company has invested more than 100 million to build a public technical service platform in line with GMP specifications, including testing platform, four large and medium-sized test platforms (chemical drug synthesis pilot test platform, oral solid preparation platform, traditional Chinese medicine extraction platform, sterile liquid preparation workshop – including eye drops). It has more than 60 professional technicians, of which 60% have bachelor’s degrees in biomedicine related majors.
At present, Boji science and technology park has obtained the drug production license for tablets, hard capsules, granules, powders, pretreatment and extraction of traditional Chinese medicine and APIs, and can provide services such as process amplification research, clinical simulant, clinical trial drug production, MAH settlement, pilot and commercial batch production, investment and financing of innovative drug projects.
The relevant person in charge of Boji science and Technology Park said that in the future, the science and technology park will make use of its advantages in the field of biomedicine, continue to promote the process of independent innovation and independent R & D, increase R & D investment, strive to obtain more scientific and technological achievements and drug approvals, serve more high-quality projects, and create a new highland in the region of the biomedical industry chain.
